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Opinion statement
Brain metastases are a major clinical challenge occurring in up to 60% of patients
suffering from metastatic melanoma. They cause significant clinical symptoms and impair
the overall survival prognosis. The introduction of targeted therapies including BRAF and
MEK inhibitors as well as CTLA-4 and PD-1 axis targeting immune checkpoint inhibitors
have dramatically improved the treatment and prognosis of patients with extracranial
metastatic melanoma. Although, similar response rates for extra- and intracranial metas-
tases have been reported, only few data from brain metastasis specific trails are available
so far. The following review will provide an overview on the currently available data on
targeted therapies, remaining questions and the most important side effects in the special
clinical situation of melanoma brain metastases.
Introduction
Brain metastases (BM) are a clinical challenge in
the treatment of melanoma patients. Up to 60% of
patients suffering from metastatic melanoma devel-
op this life treating and quality of life impairing
complication during their course of disease [2].
Melanoma has a particularly high risk to spread
to the brain compared to other frequent sources
of BM like lung and breast cancer. The median
survival after diagnosis of symptomatic BM tradi-
tionally ranged from 3.4 to 13.2 months [65].
New targeted treatment modalities, including
BRAF and MEK inhibitors as well as immune
checkpoint inhibitors, have revolutionized the
treatment of metastatic melanoma patients in the
last decade [40, 71]. Effective, rapid responses to
BRAF inhibitors and long lasting efficacy of im-
mune checkpoint inhibitors have entered the every-
day practice. However, all data on the natural
course of melanoma brain metastases remains from
the era before the availability of targeted therapies.
Therefore the course of disease may have signifi-
cantly changed as, for example, Trastuzumab has
significantly changed treatment and prognosis of
metastatic breast cancer [32]. However, to this date,
the incidence of BM has not decreased since the
introduction of the new generation targeted
therapies in metastatic melanoma. Additionally, BM
are still frequently the first site of progression,
making BM treatment a particularly important as-
pect of melanoma therapy [17, 38]. Approximately
one third of melanoma BM patients will die from
BM progression, while another third dies from the
combined progression of intra- and extracranial
metastases [10]. Therefore, treatment strategies have
to carefully address this specific progression pattern
and combine effective intra- and extracranial treat-
ment approaches.
Carefully designed trials specially concentrating on
brain metastatic endpoints are therefore urgently
needed. Here, especial emphasis should be given to
intracranial response and the potential to prevent
symptomatic brain metastases [50]. Further, brain
metastasis-specific endpoints like survival without neu-
rological deterioration should be considered and inves-
tigated in order to improve the therapy sequence for
patients suffering from melanoma brain metastases
[50]. A further specific challenge in the treatment of
melanoma BM is the relative radio-resistance of mela-
noma. Therefore, systemic therapies are applied more
frequently in oligo- to asymptomatic BM patients as first
line treatment approach than in most other BM causing
entities [1, 43]. The following review will provide an
overview on the available targeted therapies in melano-
ma and their efficacy in the special context of BM.
BRAF tyrosine kinase inhibitors
Activatingmutations of the v-Raf murine sarcoma viral oncogene homolog B (BRAF)
gene occur in up to 50% ofmelanoma patients, with a higher frequency among
very young patients. Here, the V600E pointmutationwith substitution of valine
to glutamate at codon 600 is the most frequently observed mutation (980%)
followed by the V600Kmutation (14%) [36]. The presence of a BRAFmutation
is most likely not associated with an increased risk to develop BM [36]. BRAF
tyrosine kinase inhibitors like Vemurafenib and Dabrafenib effectively inhibit
the downstream activated MAPK (mitogen-activated protein kinase) pathway
and have shown improved disease control rates (CR + PR + SD) of up to 92%,
significantly prolonged progression and overall survival compared to
chemotherapy in extracranial metastatic melanoma [23, 42].
Predictive biomarkers
The presence of the V600E and at a lesser extend the V600K BRAF mutation is
highly predictive for the response to BRAF inhibitors. The most frequently
occurring point mutation V600E can reliable detected with the mutation spe-
cific antibody VE1 [12]. However, DNA-basedmethods like gene sequencing or
the COBAS test can also identify less frequently occurring point mutations.
Therefore, the sequence of using immunohistochemistry (VE1 antibody) as a
screeningmethod followed by a DNA-based method in case of a negative result
to rule out raremutation types is currently proposed for routine clinical practice
[51]. Importantly, the BRAF mutation presents with a high concordance be-
tweenmetastases from different sites if using the V600E BRAFmutation specific
antibody VE1 [11, 28].
Clinical efficacy of BRAF inhibitors in melanoma brain metastases
Initial licensing phase III trials excluded patients with active or untreated
melanoma BM. However, subsequent BM specific trials have shown
similar intra- and extracranial response rates for BRAF inhibitor
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monotherapy. The BREAK-MB phase II study was the first to specifically
address the efficacy of BRAF inhibition in patients with BRAF mutation
harboring brain metastatic melanoma [34]. Overall, 172 melanoma BM
patients without (n = 89; cohort A) or with (n = 83; cohort B) prior local
BM treatment were included. Intra- (cohort A: 81.1%, cohort B: 89.2%)
and extracranial (cohort A: 79.7%, cohort B: 83.1%) disease control rate
as well as overall survival (cohort A: 33.1 weeks, cohort B: 31.4 weeks)
was impressive and similar in both groups indicating that efficacy of
BRAF inhibition is also given in the context of BM recurrence (Table 1).
A phase II study of Vemurafenib in a cohort of patients with preciously
untreated (n = 90; cohort 1) and previously treated (n = 56; cohort 2)
melanoma BM presented with a very similar outcome (Table 1) [41••].
Intra- (cohort 1: 18%, cohort 2: 20%) and extracranial (cohort 1: 33%,
cohort 2: 23%) response rate was comparable as well as overall survival
(cohort 1: 8.9 months, cohort 2: 9.6 months), although numerically less
impressive compared to the responses observed for Dabrafenib.
No head to head comparisons answers the question whether to use
Vemurafenib or Dabrafenib upon the occurrence of BM. Preclinical data
suggest a better brain distribution of Dabrafenib [44, 63]. Currently, a
clinical trial tests the accumulation nucleotide-labeled Dabrafenib in
established BM as a new method to predict treatment response
(NCT02700763).
Unfortunately, the response to BRAF inhibitors is limited to few
months as almost all patients present with a disease recurrence within
12 months [35]. A mixed response can be frequently observed shortly
before the recurrence, with still stable extracranial metastases but fast
growing and multiple new BM [48]. Interestingly, the BM progression
presents with a particular pattern of multiple disseminated lesions,
which might reflect an invasive or migratory tumor cell phenotype [22].
Combination of BRAF and MEK inhibitor
As outlined, although initially highly active, almost all patients developed
resistance to BRAF inhibitors alone within 6–7 months most likely trough
mutations resulting in MAPK reactivation [56]. In line, combination of BRAF
and MEK inhibition, which inhibits the downstream activated MAPK pathways
from different sites, resulted in a significantly prolonged progression free sur-
vival in extracranial metastatic melanoma [30, 33]. The MEK inhibitor
trametinib is subject to P-glycoprotein efflux pumps, which has been shown to
limit its efficacy in experimental BM models [68]. Interestingly, a lack of P-
glycoprotein in human melanoma BM was observed, encouraging the further
clinical investigation [55]. Case series suggest that the combination might also
be safe and effective in BM patients, however definitive conclusion can only be
drawn from the currently recruiting clinical trials (Table 2) [47•].
Combination of BRAF inhibitors with radiotherapy
The combination of BRAF inhibitors and radiotherapy is subject to an
on-going discussion. Questions including the sequencing and dosing are
currently investigated in several clinical trials (Table 2). In general,
melanoma is considered a radio-resistant tumor. Only small
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retrospective case series postulate an increased response rate by the
combination of Vemurafenib and radiotherapy. This is further supported
by preclinical findings suggesting a radio-sensitizing effect of
Vemurafenib [45, 61]. On the other hand, increased side effects such as
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skin symptoms have been reported for the combination, thus potentially
limiting the clinical applicability [1, 29]. Based on these data, BRAF
inhibitors should probably be paused during the radiotherapy.
Table 2. Selected on-going trial in melanoma brain metastases
Study Type of trial Targeted therapy Combination
with radiotherapy
Intervention Primary endpoint
BRAF and MEK inhibitor therapy
NCT02537600 Phase II Vemurafenib +
combimetinib






NCT02974803 Phase II Dabrafenib +
trametinib
Stereotactic radiosurgery Concurrent dabrafenib +
trametinib with stereotactic




Immune checkpoint inhibitor monotherapy




NCT02621515 Phase II Nivolumab None Nivolumab monotherapy in BM




Combination of two immune checkpoint inhibitors
NCT02374242 Phase II Ipilimumab +
nivolumab
None Nivolumab vs. nivolumab +




NCT02460068 Phase III Ipilimumab +
nivolumab
None Fotemustin + ipilimumab vs.
Ipilimumab + nivolumab vs.
fotemustin alone in patients
with asymptomatic BM
Overall survival







Combination of immune checkpoint inhibitor with radiotherapy
NCT02097732 Phase II Ipilimumab Stereotactic radiosurgery Ipilimumab induction flowed
by stereotactic radiosurgery
and ipilimumab in patients
with oligo- to asymptomatic
BM
Local control rate




1 year survival rate












NCT02681549 Phase II Pembrolizumab +
bevacizumab
None (prior radiotherapy








NCT02452294 Phase II Buparlisib
(PI3K Inhibitor)
None Buparlisib monotherapy in






NCT01904123 Phase I WP1066
(STAT3 inhibitor)
None WP1066 monotherapy Maximum tolerated
dose
NCT02308020 Phase II Abemaciclib
(CDK inhibitor)
Abemaciclib in patients
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Side effects of BRAF inhibitors in brain metastasis patients
Classical side effects of BRAF inhibitors include gastrointestinal symptoms (diar-
rhea, nausea, vomiting), skin symptoms (cutaneous squamous cell carcinoma,
keratoacanthoma, photosensitivity reaction, hyperkeratosis, rash), fatigue, pyrexia,
and elevated liver enzymes [23, 42]. Frequency of cutaneous squamous cell
carcinoma and keratoacanthoma is lower in patients treated with the combination
of BRAF and MEK inhibitor [30]. No additional and particular no increase in
neurological side effects were observed in BM patients, showing that BRAF inhib-
itors are safe in this particular population [34, 41••].
Immune checkpoint inhibitors
Immune checkpoint inhibitors have dramatically changed the treatment of met-
astaticmelanomawith a substantial overall survival improvement [24, 57–59]. So
far, CTLA4 (cytotoxic T-lymphocyte protein 4; Ipilimumab) and PD-1 (pro-
grammed cell death 1; Nivolumab, Pembrolizumab) axis targeting immune
checkpoint inhibitors have been approved for the treatment of metastatic mela-
noma. The anti-tumor effect is mediated by T cells as immune checkpoint
inhibitors increase the tumor-specific T cell response [40]. Response assessment
might be challenging as pseudoprogression caused by the initial influx of immune
cell in the tumor tissue can mimic disease progression but may result in subse-
quent disease control [72]. Importantly, response patterns to immune checkpoint
inhibitors may differ from traditional chemotherapy and other targeted therapies.
The period to best response can be longer than with targeted therapies or che-
motherapy. Some patients present initially with a stabilization of the disease and
delayed tumor shrinkage only after several weeks or months of treatment. The
resulting responses may however be long lasting and some patients present with
disease stabilization for prolong periods [24, 57, 58]. Long-term follow-up of
patients treated in phase II and III trials with ipilimumab reveals a survival plateau
of 20% starting from 3 years and extending up to 10 years [62]. The response to
PD-1 axis targeting checkpoint inhibitors or the combination of both have shown
even more profound responses than Ipilimumab monotherapy, and the long-
term follow-up indicates an even higher survival plateau [57, 58].
Predictive biomarkers
Several potential predictive biomarkers have been postulated for the response
to immune checkpoint inhibitors [18]. For ipilimumab, some histological
characteristics like high density of tumor infiltrating lymphocytes as well as
genetic characteristics including a neo-antigen signature and high mutational
load were postulated to have a predictive potential [20, 64, 69•]. Expression of
PD-L1 on the tumor cells is a promising predictive biomarker for the response
to PD-1 axis targeting immune checkpoint inhibitors. However, the negative
predictive value of PD-L1 expression is low, as responses were also observed in a
significant fraction of patients without PD-L1 expression [67]. Here, several
different antibodies and cut off values were postulated. The probability of
response increases with the percentage of PD-L1 expressing cells, with the
highest probability in patients with 950% of tumor cells presenting with
expression [60, 70, 73]. A high density of tumor infiltrating lymphocytes as well
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as a similar frequency of PD-L1 expression as compared with extracranial tumor
sites has been reported for melanoma BM [7].
Clinical efficacy of immune checkpoint inhibitors in melanoma brain metastases
It has been of dispute whether immune checkpoint inhibitors can reveal their
full therapeutic potential in BM, as these monoclonal antibodies with a large
molecular weight are unable to cross the blood brain barrier [8, 9]. However,
the mode of action of immunotherapies has to be taken into account, as the T
cell priming influenced by immune checkpoint inhibitors may to some extent
occur in immunological sites distant from the tumor (e.g., regional lymph
nodes). T cells activated in such sites may cross an intact blood brain barrier
[52]. Further, the blood brain barrier is disrupted in contrast enhancing BM.
Consequently, anti-PD-1 immune checkpoint inhibitors may be able to enter
and inhibit the binding of PD-L1 (programmed cell death ligand 1) on tumor
cells and the PD-1 receptor on T cells in at least some areas of BM. In line with
these considerations, clinical activity of immune checkpoint inhibitor mono-
therapy was observed in melanoma BM patients. A phase II study on
ipilimumab monotherapy in patients with melanoma BM included overall 72
patients in two cohorts. Cohort A (n = 51) included asymptomatic patients
without corticosteroid treatment and cohort B (n = 21) patients with symptoms
requiring corticosteroid treatment [39]. Intra- (cohort A: 25%, cohort B: 10%)
and extracranial (cohort A: 33%, cohort B: 10%) disease control rate applying
adapted response criteria was similar, although a difference was observed
between the asymptomatic patients (cohort A) and the symptomatic ones
(cohort B). Therefore, corticosteroid treatment might impact the efficacy of
ipilimumab therapy either due to the resulting immune suppression or due to
the impaired clinical condition of the patients, which is resembled by the need
for corticosteroid treatment. Here, data from extracranial metastatic melanoma
indicates that corticosteroid treatment for the control of immune related side
effects does not alter response probability [21, 25]. In symptomatic BM patients
in need for steroid treatment, the disease progression may be too fast to allow
enough time for the immune checkpoint inhibitor to develop its full antitumor
activity. As PD-1 axis targeting immune checkpoint inhibitors have shown
higher response rates in extracranial melanoma, these might also be the more
promising agents formelanoma BMpatients. So far, however, only little data on
the intracranial efficacy of anti-PD-1 immune checkpoint inhibitor monother-
apy exists. A phase II trial on pembrolizumab monotherapy in BM patients
included different primary histologies including melanoma (n = 18) and non-
small cell lung cancer (n = 18) [19••]. Unfortunately, not all melanoma pa-
tients were eligible for response assessment, however 4/14 (28%) patients
presented with confirmed intracranial partial response and 2/14 (14%) with
stable intracranial disease, resulting in a 42% intracranial disease control rate.
Extracranial disease control was 50%, with 4/16 (25%) patients presenting with
extracranial partial or complete response and 4/16 (25%) with stable disease.
Conclusions have to be drawn with caution due to the limited number of
included patients. Nonetheless, observed response rates are promising and
currently recruiting trials are further addressing the efficacy of pembrolizumab
in patients with melanoma BM (Table 2). No results from BM specific clinical
trials, investigating the efficacy of nivolumab treatment in melanoma BM
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patients, are yet available. However, several case series indicate the safety and
efficacy of nivolumab monotherapy [6, 37]. The currently recruiting clinical
trials will provide a deeper and more profound insight in the value of immune
checkpoint inhibitor therapy in melanoma BM patients (Table 2).
Combination of immune checkpoint inhibitors with radiotherapy
Combination of radiotherapy and immune checkpoint inhibitors has shown to
increase response also in not initially radiated lesion due to the so-called abscopal
effect [49, 66]. In theory, antigen release due to cell death caused by the radiation
increases the T cell mediated immune response facilitated by the immune check-
point inhibitor treatment. Therefore, several case series postulate an increased
response rate through the combination and sequencing of immune checkpoint
inhibitors and stereotactic radiotherapy [16, 26•, 53]. However, definitive con-
clusions cannot be drawn yet but currently recruiting clinical trials addressing this
question in melanoma BM patients will provide further insights (Table 2).
Combination of immune checkpoint inhibitor and chemotherapy
As previously addressed for the combination with radiotherapy, the combina-
tion with chemotherapy is also postulated to increase antigen release and
thereby potentiate the efficacy of the immune checkpoint inhibitor therapy. A
phase II clinical trial focused on the combination of fotemustine and
ipilimumab and included a subcohort of BM patients (n = 20). Again a cohort
included patients with previous radiotherapy (n = 7) and a treatment naïve
cohort with asymptomatic BM (n = 13). Here, 10/20 (50%) patients achieved
intracranial disease control (SD + PR + CR) [15]. As a consequence, the applied
combination of fotemustine and ipilimumab is currently studied in subsequent
clinical trials (Table 2).
Combination of two immune checkpoint inhibitors
Combination approaches of ipilimumab and nivolumab were shown to result in
significantly improved progression-free survival in patients with metastatic mela-
noma [31]. However, treatment-related adverse events also increased in the
combination armwith grade 3 and 4 events occurring in up to 55% of patients. A
small case series of nine patients (6/9 with BM) populates safety of the combi-
nation of low dose ipilimumab (1mg/kg) with pembrolizumab in BMpatients as
no increase in neurological side effects was observed [27]. Again, several on-going
clinical trials are currently addressing this promising combination (Table 2).
Combination of BRAF inhibitor and immune checkpoint inhibitor
Combinationof a BRAF inhibitor, producing fast effective tumor shrinkage, and an
immune checkpoint inhibitor with slowly occurring but potentially long-lasting
response would be tempting. Unfortunately, initial safety data revealed a marked
liver toxicity of the combination [54]. Sequencing with induction of the BRAF
inhibitor and switch to the immune checkpoint inhibitor after fewweeksmight be
an interesting strategy, which is currently subject to clinical trials (Table 2) [3].
Side effects in brain metastasis patients
PD-1 axis targeting immune checkpoint inhibitors are generally better tolerated
compared to CTLA-4 immune checkpoint inhibitors [58]. The side effects are
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mostly caused by the increased immune response and encompass several auto-
immune mediated side effects. Most frequent adverse events in patients treated
with PD-1 axis targeting immune checkpoint inhibitors are colitis, pneumonitis,
skin reactions, and endocrine (thyreoiditis, hypophysitis) adverse events [57, 58].
Similarly, diarrhea, rash, puritus, liver enzyme increase, and endocrine
(thyreoiditis, hypophysitis) adverse events are the most common one in
ipilimumab-based treatment [24]. The side effect profile among BM patients
presented to be not significantly different compared to patients without brain
metastases, especially no particular increase in neurological side effects was ob-
served [19••, 39]. Pseudoprogressionwith resulting symptoms due to the volume
increase was occasionally reported for BMpatients, especially for the combination
of immune checkpoint inhibitors and stereotactic radiosurgery [14, 26•].
Conclusions
The development of several new systemic treatment options including, BRAF
and MEK as well as CTLA-4 and PD-1 targeting immune checkpoint inhibitors
have revolutionized the daily practice of melanoma treatment [40]. Early BM-
specific clinical studies have postulated comparable intra- and extracranial
response rates for this new generation of targeted therapies [19••, 34, 39, 42].
Although encouraging, several important questions on the combination, the
sequencing or the concomitant application of radiotherapy remain unan-
swered. The currently recruiting BM-specific trials are likely to answer some of
these questions and give a further direction for the optimal treatment combi-
nation in melanoma BM patients (Table 2). Further, the next generation of
targeted and immune therapies is in the pipeline. Here, PI3K or CDK inhibition
might be promising as well as immunemodulating therapies targeting e.g., PD-
L1, Lag3 or Tim3 [4, 5, 13, 46]. In conclusion, targeted therapies including BRAF
inhibitors and immune checkpoint inhibitors have become an important
backbone in the treatment ofmelanoma BM and the on-going clinical trials will
further redefine the clinical practice in this particular patient cohort.
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